Novel Immunotherapeutics for Inflammatory Injury, Fibrosis and Vascular Leak
Major advances that target runaway inflammation and unremitting vascular leakage are underway to reduce human suffering and improve survival.
At Aqualung Therapeutics, we are committed to changing medicine for the good by leveraging our breakthrough discoveries to deliver novel therapeutics that can literally change the world.
Our Pipeline
Our successful therapeutic development is focused on providing novel therapies for vexing unmet medical needs using diverse non-overlapping strategies emanating from our robust scientific discoveries
Latest Aqualung Therapeutics News
Aqualung Therapeutics publishes report of early results in Phase 2a PUERTA Clinical trial in ARDS showing ALT-100 mAb clinical safety and efficacy
April 1, 2026
Aqualung Therapeutics Receives FDA Clearance for Phase 2a LungFibrosis Study
December 5, 2025
Aqualung Therapeutics Receives NIH STTR Grant Award $1.2M to develop ALT-100 mAb for Progressive Pulmonary Fibrosis
September 15, 2025
Get in touch with us!
Please contact us if you are interested in “learning more” or seeking an investor presentation.